Two Healthcare Stocks Trading Up to 46% Below Fair Value
A recent analysis suggests that AbbVie (ABBV) and Merck (MRK) are trading significantly below their estimated fair values, with discounts up to 46.2%, presenting a 12.2% discount opportunity in a US market that has risen 24% over the past year.
Key Numbers
Over the past week, the US market has remained flat, yet it has seen a significant increase of 24% over the past year, with earnings forecasted to grow by 19% annually. In this context, an analysis by Simply Wall St. identified several stocks estimated to be undervalued, including AbbVie (ABBV) and Merck (MRK) in the healthcare sector.
Details
According to the analysis, AbbVie trades at a discount of up to 46.2% to its estimated fair value, while Merck shows a similar discount opportunity. These estimates are based on discounted cash flow (DCF) models and peer comparisons.
Context
The analysis comes amid a strong US market performance, with a 24% rise over 12 months and expectations of 19% annual earnings growth. This growth may enhance the appeal of undervalued stocks.
What This Means for Investors
These stocks offer a potential opportunity for investors seeking undervalued investments in a rising market. However, investors should conduct their own research and consider factors such as growth prospects and risks before making decisions.
Frequently Asked Questions
Found this useful? Share it